Market closedNon-fractional
Akero Therapeutics/AKRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Akero Therapeutics
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Ticker
AKRO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
59
Website
akerotx.com
AKRO Metrics
BasicAdvanced
$2B
Market cap
-
P/E ratio
-$3.22
EPS
-0.31
Beta
-
Dividend rate
Price and volume
Market cap
$2B
Beta
-0.31
Financial strength
Current ratio
30.116
Quick ratio
29.864
Long term debt to equity
4.222
Total debt to equity
4.222
Interest coverage (TTM)
-56.17%
Management effectiveness
Return on assets (TTM)
-20.23%
Return on equity (TTM)
-31.11%
Valuation
Price to book
2.32
Price to tangible book (TTM)
2.32
Price to free cash flow (TTM)
-10.112
Growth
Earnings per share change (TTM)
20.87%
3-year earnings per share growth (CAGR)
8.88%
What the Analysts think about AKRO
Analyst Ratings
Majority rating from 10 analysts.
AKRO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$53M
-3.27%
Profit margin
0.00%
NaN%
AKRO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.60
-$0.71
-$0.99
-$0.90
-
Expected
-$0.63
-$0.68
-$0.86
-$0.95
-$0.94
Surprise
-4.46%
4.22%
14.95%
-5.55%
-
AKRO News
AllArticlesVideos
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
PRNewsWire·1 week ago
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
GlobeNewsWire·4 weeks ago
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Akero Therapeutics stock?
Akero Therapeutics (AKRO) has a market cap of $2B as of July 27, 2024.
What is the P/E ratio for Akero Therapeutics stock?
The price to earnings (P/E) ratio for Akero Therapeutics (AKRO) stock is 0 as of July 27, 2024.
Does Akero Therapeutics stock pay dividends?
No, Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Akero Therapeutics dividend payment date?
Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Akero Therapeutics?
Akero Therapeutics (AKRO) has a beta rating of -0.31. This means that it has an inverse relation to market volatility.
Buy or sell Akero Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.